Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 10/20 | 0.38 |
| ▸ | HTT | P42858 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | THRB | P10828 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | PKM | P14618 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5322238 | 0.86 | — | — | |
| SCHEMBL13527664 | 0.82 | NPSR1 (0.46) | GAAALDH1A1HTTKDM4ESMN1; SMN2 | |
| SCHEMBL12909322 | 0.82 | — | — | |
| SCHEMBL13165521 | 0.82 | NPSR1 (0.46) | GAAALDH1A1HTTKDM4ESMN1; SMN2 | |
| SCHEMBL8060957 | 0.82 | NPSR1 (0.46) | GAAALDH1A1HTTKDM4ESMN1; SMN2 | |
| SCHEMBL18951716 | 0.81 | KDM4E (0.38) | LMNAALDH1A1HTTKDM4EMAPT | |
| SCHEMBL201002 | 0.80 | GAA (0.41) | LMNAGAAALDH1A1HTTKDM4E | |
| SCHEMBL6445312 | 0.78 | ALDH1A1 (0.39) | LMNAGAAALDH1A1HTTKDM4E | |
| SCHEMBL4768884 | 0.78 | HSD17B10 (0.52) | LMNAGAAALDH1A1HTTKDM4E | |
| SCHEMBL13671235 | 0.77 | LMNA (0.38) | LMNAGAAALDH1A1HTTKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113087684-B | Application of bis (triphenylphosphine) carbonyl ruthenium dichloride monohydrate | 浙江工业大学 | 2022-06-21 | — | — | CN | claimed |
| CN-113087684-A | Application of bis (triphenylphosphine) carbonyl ruthenium dichloride monohydrate | 浙江工业大学 | 2021-07-09 | — | — | CN | claimed |
| CN-113201020-B | Preparation method of bis (triphenylphosphine) carbonyl ruthenium dichloride monohydrate | 浙江工业大学 | 2022-10-04 | — | — | CN | disclosed |
| CN-113087684-B | Application of bis (triphenylphosphine) carbonyl ruthenium dichloride monohydrate | 浙江工业大学 | 2022-06-21 | — | — | CN | disclosed |
| CN-113201020-A | Preparation method of bis (triphenylphosphine) carbonyl ruthenium dichloride monohydrate | 浙江工业大学 | 2021-08-03 | — | — | CN | disclosed |
| CN-113087684-A | Application of bis (triphenylphosphine) carbonyl ruthenium dichloride monohydrate | 浙江工业大学 | 2021-07-09 | — | — | CN | disclosed |
| WO-2020020101-A1 | BENZISOSELENAZOLIDONE AMINE COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 上海星叶医药科技有限公司 | 2020-01-30 | — | — | WO | disclosed |
| EP-3002283-A1 | THIAZOLE DERIVATIVES | Kyowa Hakko Kirin Co., Ltd. (JP) | 2016-04-06 | — | — | EP | disclosed |
| US-8889718-B2 | Thiazole derivatives | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2014-11-18 | — | — | US | disclosed |
| US-8853133-B2 | Analyte determination utilizing mass tagging reagents comprising a non-encoded detectable label | DH TECHNOLOGIES DEVELOPMENT PTE. LTD. (SG) | 2014-10-07 | — | — | US | disclosed |
| US-8853133-B2 | Analyte determination utilizing mass tagging reagents comprising a non-encoded detectable label | DH TECHNOLOGIES DEVELOPMENT PTE. LTD. (SG) | 2014-10-07 | — | — | US | disclosed |
| US-20100152162-A1 | THERAPEUTIC AND/OR PREVENTIVE AGENTS FOR A SLEEP DISORDER | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2010-06-17 | — | — | US | disclosed |
| US-7718808-B2 | Thiazole derivatives | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2010-05-18 | — | — | US | disclosed |
| US-7718808-B2 | Thiazole derivatives | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2010-05-18 | — | — | US | disclosed |
| US-20090005355-A1 | Piperidine Compound and Process for Preparing the Same | TANABE SEIYAKU CO., LTD. (JP) | 2009-01-01 | — | — | US | disclosed |
| US-20090005355-A1 | Piperidine Compound and Process for Preparing the Same | TANABE SEIYAKU CO., LTD. (JP) | 2009-01-01 | — | — | US | disclosed |
| US-20080241955-A1 | Methods, Mixtures, Kits And Compositions Pertaining To Analyte Determination | APPLERA CORPORATION (US) | 2008-10-02 | — | — | US | disclosed |
| US-20070105919-A1 | adenosine A2A receptor antagonists; N-[4-(2-Furyl)-5-(4-pyridyl)thiazol-2-yl]pyridine-4-carboxamide; treatment of Parkinson's disease, Alzheimer's disease, progressive supranuclear palsy, AIDS encephalopathy, nerve system disorders | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2007-05-10 | — | — | US | disclosed |
| US-20070105919-A1 | adenosine A2A receptor antagonists; N-[4-(2-Furyl)-5-(4-pyridyl)thiazol-2-yl]pyridine-4-carboxamide; treatment of Parkinson's disease, Alzheimer's disease, progressive supranuclear palsy, AIDS encephalopathy, nerve system disorders | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2007-05-10 | — | — | US | disclosed |
| WO-2006050054-A2 | COMPOUNDS AND METHODS OF USE THEREOF | NUADA, LLC (US) | 2006-05-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080241955-A1 | Methods, Mixtures, Kits And Compositions Pertaining To Analyte Determination | SRMS, KLK3, MPO | LMNA 868/4885GAA 959/4885ALDH1A1 130/4885 |
| US-20070105919-A1 | adenosine A2A receptor antagonists; N-[4-(2-Furyl)-5-(4-pyridyl)thiazol-2-yl]pyridine-4-carboxamide; treatment of Parkinson's disease, Alzheimer's disease, progressive supranuclear palsy, AIDS encephalopathy, nerve system disorders | ADORA2A, ADORA3, ADORA1 | LMNA 2878/4885GAA 3099/4885ALDH1A1 2843/4885 |
| US-20090005355-A1 | Piperidine Compound and Process for Preparing the Same | AVPR1B, HRH4, PRLHR | LMNA 4260/4885GAA 4770/4885ALDH1A1 2868/4885 |
| US-20100152162-A1 | THERAPEUTIC AND/OR PREVENTIVE AGENTS FOR A SLEEP DISORDER | HCRTR1, MTNR1A, HCRTR2 | LMNA 3303/4885GAA 3158/4885ALDH1A1 638/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.